| pubmed-article:11482747 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11482747 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11482747 | lifeskim:mentions | umls-concept:C0878773 | lld:lifeskim |
| pubmed-article:11482747 | lifeskim:mentions | umls-concept:C0388753 | lld:lifeskim |
| pubmed-article:11482747 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:11482747 | pubmed:dateCreated | 2001-8-2 | lld:pubmed |
| pubmed-article:11482747 | pubmed:abstractText | Tolterodine is a bladder-selective antimuscarinic agent designed for the treatment of overactive bladder. Traditional antimuscarinic therapies are poorly tolerated due to a high incidence of anticholinergic adverse events and consequently few patients remain on long term therapy. | lld:pubmed |
| pubmed-article:11482747 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11482747 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482747 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11482747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482747 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11482747 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11482747 | pubmed:issn | 1170-229X | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:JonasUU | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:WeilCC | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:JacquetinBB | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:AbramsPP | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:WyndaeleJ JJJ | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:TammelaTT | lld:pubmed |
| pubmed-article:11482747 | pubmed:author | pubmed-author:Malone-LeeJJ | lld:pubmed |
| pubmed-article:11482747 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11482747 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:11482747 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11482747 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11482747 | pubmed:pagination | 551-60 | lld:pubmed |
| pubmed-article:11482747 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:meshHeading | pubmed-meshheading:11482747... | lld:pubmed |
| pubmed-article:11482747 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11482747 | pubmed:articleTitle | Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. | lld:pubmed |
| pubmed-article:11482747 | pubmed:affiliation | Bristol Urological Institute, Southmead Hospital, Westbury-on-Trym, England. paul_abrams@bui.ac.uk | lld:pubmed |
| pubmed-article:11482747 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11482747 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11482747 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11482747 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11482747 | lld:pubmed |
